Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.

RT @CR_AACR: In the Spotlight— Striking the Balance with a PD-L1×4–1BB Bispecific Antibody, by JongHoon Ha et al. https://t.co/RhvQdFO7dz @…

In the Spotlight— Striking the Balance with a PD-L1×4–1BB Bispecific Antibody, by JongHoon Ha et al. https://t.co/RhvQdFO7dz @MDAndersonNews https://t.co/fii0Wv591g

The tetravalent PD-L1×4-1BB bispecific antibody ATG-101 activates 4-1BB+ T cells in a PD-L1 cross-linking–dependent manner, minimizing the hepatotoxicity of existing 4-1BB agonists and suppressing growth of ICI-resistant tumors. https://t.co/qwxc4UzFds

RT @wenjiang_nano: Check out the latest commentary ⁦@CR_AACR⁩ by talented #radonc resident and #physicianscientist ⁦@adam_grippin⁩ on a new…